IMMUNOTHERAPY WITH A POLYVALENT MELANOMA VACCINE PLUS BCG IN STAGE IV

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究旨在确定卡介苗（BCG），一种牛结核菌与黑色素瘤疫苗（C-VAX）的组合是否比BCG和安慰剂更有效地刺激针对黑色素瘤的免疫应答，提高总生存率，并增加手术后复发的延迟。这项研究正在进行，因为目前没有批准的黑色素瘤治疗，这缩短了复发的时间。人们希望C-VAX，一种实验性疫苗，将有好处，这将有助于缓解这一问题。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to determine whether Bacillus Calmette Guerin (BCG), a bovine tubercle germ in combination with melanoma vaccine (C-VAX) is more effective than BCG and a placebo in stimulation of an immune response against melanoma, in improving overall survival, and increasing a delay in recurrence following surgery. This research is being done because there is no currently approved treatment of melanoma, which prolongs the time to recurrence. It is hoped that C-VAX, an experimental vaccine, will have benefits, which will help alleviate this problem.